Herpes Zoster Shingles Varicella-Zoster Virus Reactivation Herpes zoster Shingles Varicella-zoster virus Postherpetic neuralgia Incidence Hospitalization Mortality Survival Epidemiology Retrospective study Administrative database Real-world evidence Thailand Adults Older adults
Conditions
Interventions
The study population includes adults aged 18 years or older with at least one outpatient or inpatient encounter coded with ICD-10 code B02.xx between January 1, 2016 and December 31, 2024. Only the fi
Other
zoster
Sponsors
GlaxoSmithKline
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Adult patients aged 18 years or older. 2. At least one outpatient encounter with a primary diagnosis of herpes zoster (ICD-10 code B02.xx) or one inpatient encounter with a primary or secondary diagnosis of herpes zoster (ICD-10 code B02.xx) between 2016 and 2024. Only the first herpes zoster episode during the study period will be included. 3. Diagnosis of herpes zoster identified using ICD-10 code B02.xx.
Exclusion criteria
Exclusion criteria: Subjects who meet any of the following criteria will be excluded from participation in this study: 1. Key demographic variables (age or sex) are missing 2. Patients had an HZ diagnosis revisit during study period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Annual incidence of herpes zoster 2016 to 2024 Annual incidence | — |
Secondary
| Measure | Time frame |
|---|---|
| demographic and clinical characteristics of patients with hospitalizations with HZ 2016-2024 number and percentage count,HZ-related complications 2016-2024 Number rand percentage,HCRU, length of stay (LOS), hospitalization rate, and case fatality rate 2016-2024 Number and percentage,Factor associated in hospital mortality 2016-2024 Odd ratio,Survival outcome at 365-day 2016-2024 Hazard ratio | — |
Countries
Timor-Leste
Contacts
Public ContactChadakan Yan
GlaxoSmithKline (Thailand) Ltd.
Outcome results
None listed